A mathematical model of breast and ovarian cancer treated with paclitaxel

Mathematical Biosciences

Volumn 146, Issue 2, 1997, Pages 89-113

  Panetta, John Carl ^a  

^a BEHREND COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PACLITAXEL;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CELL PROLIFERATION; GROWTH INHIBITION; MATHEMATICAL MODEL; OVARY CANCER;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; BONE MARROW; BREAST NEOPLASMS; CELL CYCLE; CELL DIVISION; FEMALE; HUMANS; MATHEMATICS; MODELS, BIOLOGICAL; OVARIAN NEOPLASMS; PACLITAXEL;

EID: 0030867447     PISSN: 00255564     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0025-5564(97)00077-1     Document Type: Article

References (18)

1. W. W. ten Bokkel Huinink, E. Eisenhauser, and K. Swenerton, Preliminary evaluation of a multicenter randomized comparative study of TAXOL (paclitaxel) dose and infusion length in platinum-treated ovarian cancer. Cancer Treat. Rev. 19(Suppl. C):79-86 (1993).
2. J. M. Nabholtz, K. Gelmon, M. Bontenbal, M. Spielmann, G. Catimel, P. Conte, U. Klaassen, M. Namer, J. Bonneterre, P. Fumoleau, and B. Winograd, Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J. Clin. Oncol. 14(6):1858-1867 (1996).
3. K. A. Gelmon, Biweekly paclitaxel in the treatment of patients with metastatic breast cancer. Semin. Oncol. 22(5):117-122 (1995).
4. G. Fountzilas, A. Athanassiades, T. Giannakakis, D. Bafaloukos, K. Karakousis, N. Dombros, P. Kosmidis, and D. Skarlos, A phase II study of paclitaxel in advanced breast cancer resistant to anthracyclines. Eur. J. Cancer 32A(1):47-51 (1996).
5. M. M. Lopes, E. G. Adams, T. W. Pitts, and B. K. Bhuyan, Cell kill kinetics and cell cycle effects of taxol on human and hamster ovarian cell lines. Cancer Chemother. Pharmacol. 32:235-242 (1993).
6. J. D. Hainsworth and F. A. Greco, Paclitaxel administered by 1-hour infusion. Cancer 74(4): 1377-1382 (1994).
7. U. Klaassen, H. Wilke, D. Strumberg, W. Eberhardt, M. Korn, and S. Seeber, Phase I study with a weekly l h infusion of paclitaxel in heavily pretreated patients with metastatic breast and ovarian cancer. Eur. J. Cancer 32A(3):547-549 (1996).
8. J. Riondel, M. Jacrot, F. Picot, H. Beriel, C. Mouriquand, and P. Potier, Therapeutic response to taxol of six human tumors xenografted into nude mice. Cancer Chemother. Pharmacol. 17:137-142 (1986).
9. W. H. Wilson, S. L. Berg, G. Bryant, R. E. Wittes, S. Bates, A. Fojo, S. M. Steinberg, B. R. Goldspiel, J. Herdt, J. O'Shaughnessy, F. M. Balis, and B. A. Chabner, Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I/II trial of 96-hour infusion. J. Clin. Oncol. 12(8):1621-1629 (1994).
10. G. F. Webb, A cell population model of periodic chemotherapy treatment. In Biomedical Modeling and Simulation, Elsevier, 1992, pp. 83-92.
11. G. F. Webb, A nonlinear cell population model of periodic chemotherapy treatment. Recent Trends Ordinary Differential Equations Ser. Appl. Anal. 1:569-583 (1992).
12. J. C. Panetta and J. A. Adam, A mathematical model of cycle-specific chemotherapy. Math. Comput. Model. 22(2):67-82 (1995).
13. J. A. Adam and J. C. Panetta, A simple mathematical model and alternative paradigm for certain chemotherapeutic regimens. Math. Comput. Model. 22(8):49-60 (1995).
14. F. L. Baker, L. J. Sanger, R. W. Rodgers, K. Jabboury, and O. R. Mangini, Cell proliferation kinetics of normal and tumor tissue in vitro: quiescent reproductive cells and the cycling reproductive fraction. Cell Prolif. 28:1-15 (1995).
15. M. Eisen and J. Schiller, Stability analysis of normal and neoplastic growth. Bull. Math. Biol. 39(5):597-605 (1977).
16. B. G. Birkhead, E. M. Rakin, S. Gallivan, L. Dones, and R. D. Rubens, A mathematical model of the development of drug resistance to cancer chemotherapy. Eur. J. Cancer Clin. Oncol. 23(9):1421-1427 (1987).
17. M. C. Mackey, Unified hypothesis for the origin of aplastic anemia and periodic hematopoiesis. Blood 51(5):941-956 (1978).
18. R. C. Jackson, The problem of the quiescent cancer cell. Adv. Enzyme Regul. 29:27-46 (1989).